Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPI-504 plus Trastuzumab in HER2+ Metastatic Breast Cancer
NCT00817362Phase 2Terminated
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Mar 2009
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of retaspimycin in HER2-positive breast cancer, sponsored by Infinity Pharmaceuticals, Inc. Primary endpoints: Overall Response Rate and Safety and Tolerability. Started Mar 2009; status: terminated.
02
Drugs
retaspimycin
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT00817362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00817362.